Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 02-22-161-060 | Registry Identifier | Idem + antihistamines, amantadine in the evolution of COVID |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina | OTHER |
| Institut CatalĂ de la Salut | OTHER |
Not provided
Not provided
Not provided
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.
Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease.
The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.
The number COVID cases would be related to hospital admissions. Among hospital admissions, the number of previous treatments, the length of admission, the need or not of the Intensive Care Unit (ICU) and their final status (survivors or non survivors) would be studied.
If patients that previously received the influenza vaccine or treated with ACEI, ARB, antihistamines or amantadine showed a better evolution, it would be proposed to extend vaccination and the inclusion of ACE inhibitors, ARB, antihistamines or amantadine in the treatment of infection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hospital admissions, postcovid syndrome and thrombosis among COVID cases in CST population | Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020. No intervention is performed. |
| |
| Evolution of COVID cases in patients receiving antihistamines | COVID cases, hospital admissions, postcovid syndrome, thrombosis and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with antihistamines. No intervention is performed. |
| |
| Evolution of COVID cases in patients receiving amantadine. | COVID cases, hospital admissions, postcovid syndrome, thrombosis and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with amantadine. No intervention is performed. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Antihistamine | Drug | No intervention is performed. We propose an observational study. |
|
| Measure | Description | Time Frame |
|---|---|---|
| hospital output | exitus vs hospital output | from March 1, 2020. |
| Measure | Description | Time Frame |
|---|---|---|
| hospital stay | length of the hospital stay | From March 1, 2020. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
All hospital admissions in the Hospital of Terrassa from March 1, 2020 were innitially included.
Population of reference: the population assigned to the Terrassa Health Consortium population.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Anna PuigdellĂvol-Sánchez, Ph.D. | Contact | 34-93-5884555 | apuigdellivol@cst.cat | |
| Mar Muñoz | Contact | 34-93-7003657 | 1895 | Reserca@cst.cat |
| Name | Affiliation | Role |
|---|---|---|
| Anna PuigdellĂvol-Sánchez, Ph D | Consorci Sanitari de Terrassa | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital de Terrassa | Recruiting | Terrassa | Barcelona | 08227 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32052466 | Background | Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020 May;92(5):479-490. doi: 10.1002/jmv.25707. Epub 2020 Mar 3. | |
| 32129518 | Background | Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 Aug;81(5):537-540. doi: 10.1002/ddr.21656. Epub 2020 Mar 4. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D007251 | Influenza, Human |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D006633 | Histamine Antagonists |
| D000547 | Amantadine |
| D000806 | Angiotensin-Converting Enzyme Inhibitors |
| D007252 | Influenza Vaccines |
| ID | Term |
|---|---|
| D018494 | Histamine Agents |
| D018377 | Neurotransmitter Agents |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Amantadine | Drug | No intervention is performed. We propose an observational study |
|
|
| ACEI | Drug | No intervention is performed. We propose an observational study. |
|
|
| ARB | Drug | No intervention is performed. We propose an observational study. |
|
|
| Influenza vaccine and COVID | Other | No intervention is performed. We propose an observational study. |
|
| 33465426 | Background | Moran Blanco JI, Alvarenga Bonilla JA, Homma S, Suzuki K, Fremont-Smith P, Villar Gomez de Las Heras K. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients. Pulm Pharmacol Ther. 2021 Apr;67:101989. doi: 10.1016/j.pupt.2021.101989. Epub 2021 Jan 16. |
| 33604795 | Background | Cortes-Borra A, Aranda-Abreu GE. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. Pharmacol Rep. 2021 Jun;73(3):962-965. doi: 10.1007/s43440-021-00231-5. Epub 2021 Feb 18. |
| 39459868 | Result | Puigdellivol-Sanchez A, Juanes-Gonzalez M, Calderon-Valdiviezo A, Valls-Foix R, Gonzalez-Salvador M, Lozano-Paz C, Vidal-Alaball J. COVID-19 in Relation to Polypharmacy and Immunization (2020-2024). Viruses. 2024 Sep 27;16(10):1533. doi: 10.3390/v16101533. |
| 40508884 | Result | Puigdellivol-Sanchez A, Juanes-Gonzalez M, Calderon-Valdiviezo AI, Losa-Puig H, Gonzalez-Salvador M, Leon-Perez M, Pueyo-Anton L, Franco-Romero M, Lozano-Paz C, Cortes-Borra A, Valls-Foix R. COVID-19 Pandemic Waves and 2024-2025 Winter Season in Relation to Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Amantadine. Healthcare (Basel). 2025 May 27;13(11):1270. doi: 10.3390/healthcare13111270. |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D009976 | Orthomyxoviridae Infections |
| D020164 | Chemical Actions and Uses |
| D045505 | Physiological Effects of Drugs |
| D000218 | Adamantane |
| D001952 | Bridged-Ring Compounds |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011480 | Protease Inhibitors |
| D004791 | Enzyme Inhibitors |
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |